Contraceptive Management for Bleeding Control

Initial Assessment and Management

Before switching contraceptive methods, rule out underlying gynecologic problems including pregnancy, sexually transmitted diseases, new pathologic uterine conditions, and drug interactions, as recommended by the Centers for Disease Control and Prevention 1
If no underlying pathology is identified and bleeding persists despite short-term treatment attempts, switching contraceptive methods is appropriate, according to the Centers for Disease Control and Prevention 1

The American College of Obstetricians and Gynecologists recommends considering a levonorgestrel intrauterine device, which provides excellent contraceptive efficacy with eventual amenorrhea in most users, though initial irregular bleeding is common, as stated in the MMWR Recommendations and Reports 1
Estetrol 15 mg/drospirenone 3 mg demonstrates regular scheduled bleeding patterns without the blood pressure effects of synthetic estrogens, as reported in Hypertension 2

The American Heart Association advises avoiding drospirenone formulations in patients with venous thromboembolism risk factors, as drospirenone carries a higher venous thromboembolism risk compared to levonorgestrel-containing pills, with a hazard ratio of 1.77 (95% CI 1.33-2.35), as noted in a medical guideline 3

The Centers for Disease Control and Prevention recommends assessing bleeding patterns at 3-month follow-up 1
Monitor blood pressure, as norethindrone formulations may have different cardiovascular effects than drospirenone, as reported in Hypertension 2
If breakthrough bleeding continues beyond 3 cycles on the new formulation, consider non-hormonal contraceptive methods, according to the Centers for Disease Control and Prevention 1